.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,251,895

« Back to Dashboard

Claims for Patent: 6,251,895

Title: Olanzapine dihydrate D
Abstract:The present invention provides the novel Dihydrate D 2-methyl-thieno-benzodiazepine and a formulation therefor.
Inventor(s): Larsen; Samuel Dean (West Lafayette, IN), Nichols; John Richard (Merscyside, GB), Reutzel; Susan Marie (Indianapolis, IN), Stephenson; Gregory Alan (Fishers, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:08/935,883
Patent Claims: 1. Olanzapine dihydrate D, which has an X-ray powder diffraction pattern with the following interplanar spacings (d) in Angstroms:

2. Olanzapine dihydrate D as claimed in claim 1 wherein the interplanar spacings have the following relative intensities (I/I.sub.1)

3. Olanzapine dihydrate D of claim 1 in substantially pure form.

4. Olanzapine dihydrate D of claim 2 in substantially pure form.

5. Olanzapine dihydrate D of claim 4 which contains less than 2% olanzapine dihydrate B.

6. A pharmaceutical formulation comprising as an active ingredient olanzapine dihydrate D of claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient.

7. A pharmaceutical formulation comprising as an active ingredient olanzapine dihydrate D of claim 2 and a pharmaceutically acceptable carrier, diluent, or excipient.

8. A pharmaceutical formulation comprising as an active ingredient olanzapine dihydrate D of claim 3 and a pharmaceutically acceptable carrier, diluent, or excipient.

9. A formulation of claim 6 wherein the formulation is an aqueous suspension.

10. A formulation of claim 6 wherein the formulation is a tablet.

11. A formulation of claim 8 wherein the formulation is an aqueous suspension.

12. A method for treating a psychotic condition in a mammal comprising administering an effective amount of olanzapine dihydrate D of claim 1 to the mammal.

13. A method for treating a condition selected from the group consisting of anxiety, schizophrenia, schizophreniform disorder, a functional bowel disorder, and psychosis in a mammal, comprising administering an effective amount of olanzapine dihydrate D of claim 1 to the mammal.

14. A process for preparing a crystalline olanzapine dihydrate D comprising stirring technical grade olanzapine in an aqueous solvent from about one hour to about six days until dihydrate D is formed.

15. The process of claim 14 wherein the olanzapine is stirred for at least 12 hours.

16. The process of claim 15 wherein the olanzapine is stirred for at least 24 hours.

17. The process of claim 16 wherein the olanzapine is stirred for about 5 days.

18. The process of claim 14 wherein the solvent includes a wetting agent.

19. The process of claim 14 which includes the additional step of drying the dihydrate D using a technique sufficiently mild to avoid desolvation of the dihydrate D.

20. Olanzapine dihydrate D having an X-ray powder diffraction pattern with the following interplanar spacings (d) in Angstroms:

9.45, 7.45, 5.22, 4.40, 4.35 & 4.28.

21. Olanzapine dihydrate D having an X-ray powder diffraction pattern with the following interplanar spacings (d) in Angstroms: 9.45, 7.71, 7.45, 5.22, 4.98, 4.78, 4.40, 4.35, 4.28 & 3.38.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc